🔗 Visit the ClinicalTrials.gov page for NCT02155647
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. | Lancet Oncol | 2016 | 1.82 |
| 2 | Metastatic Merkel cell carcinoma response to nivolumab. | J Immunother Cancer | 2016 | 1.40 |
| 3 | Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. | Oncoimmunology | 2015 | 1.06 |
| 4 | Cancer immunotherapy in clinical practice -- the past, present, and future. | Chin J Cancer | 2014 | 0.98 |
| 5 | Updates in Therapy for Advanced Melanoma. | Cancers (Basel) | 2016 | 0.91 |
| 6 | The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. | Oncotarget | 2016 | 0.79 |
| 7 | Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. | Sci Rep | 2016 | 0.75 |